KDM1A

(redirected from LSD1)
Also found in: Wikipedia.

KDM1A

A gene on chromosome 1p36.12 that encodes a demethylase which acts on histone H3 as a coactivator or a co-repressor, depending on the context.
References in periodicals archive ?
The oral presentation titled "Lysine-Specific Histone Demethylase, LSDI (KDM1A) As a Novel Therapeutic Target in Myeloproliferative Neoplasms," outlines the beneficial effects including a reduction in mutant cells and reversal of fibrosis by inhibiting LSD1 in a well-established mouse model of myelofibrosis.
ORYZON closed, in April 2014, a global deal with ROCHE on its first asset, ORY-1001 a LSD1 inhibitor for the treatment of leukemia and other malignancies, currently in Phase I/IIA.
The agreement also includes an initial two-year collaborative research program between Oryzon and Roche s New York-based Translational Clinical Research Center (TCRC), Roche s hub for research and early development activities in North America, to better understand the potential of LSD1 inhibitors in oncology and haematology.
Retinoic acid impairs estrogen signaling in breast cancer cells by interfering with activation of LSD1 via PKA.
Salarius is working on a highly selective LSD1 inhibitor.
They discovered that inhibiting an enzyme called LSD1, using TCP, could switch these genes on again and make the cancer cells susceptible to ATRA.
The lysine demethylase LSD1 (KDM1| is required for maintenance of global DNA methylation.
LSD1, a negative regulator of cell death, regulates SA induction of Cu,Zn-SOD (Kliebenstein et al.
These are Experian Ltd, Consumer Help Services, PO Box 8000, Nottingham NG1 5GY, Equifax PLC Credit File Advice Service, PO Box 3001, Glasgow G81 2DT and Call Credit PLC, Consumer Services Team, PO Box 491, Leeds LSD1 5XX.
PTE Nisbet, 32 BDE SP SQN, 3 (UK) Regt RLC, LSD1, M/GRAD, BFPO 551
Joshi Alumkal has shown that the LSD1 (Lysine-specific demethylase 1) protein is a driver of prostate cancer cell growth and survival and that LSD1 is upregulated in aggressive prostate cancers.
The success of the company during the past year was driven by its agreement with Roche in April 2014, in which the company licensed the rights of molecule ORY-1001, a LSD1 inhibitor, to the Swiss multinational.